571150-53-3

Basic information

• Product Name: 2-AMINO-N-(3-CHLORO-4-METHOXY-PHENYL)-BENZAMIDE
• Synonyms: 2-AMINO-N-(3-CHLORO-4-METHOXY-PHENYL)-BENZAMIDE
• CAS NO: 571150-53-3
• Molecular Formula: C14H13ClN2O2
• Molecular Weight: 276.72
• Mol File: 571150-53-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-AMINO-N-(3-CHLORO-4-METHOXY-PHENYL)-BENZAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMINO-N-(3-CHLORO-4-METHOXY-PHENYL)-BENZAMIDE(571150-53-3)
• EPA Substance Registry System: 2-AMINO-N-(3-CHLORO-4-METHOXY-PHENYL)-BENZAMIDE(571150-53-3)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 571150-53-3(Hazardous Substances Data)

Usage

Chemical Class

Benzamide

Functional Groups

Amine group (2-amino)
Chloro-substituted phenyl group (3-chloro-4-methoxy-phenyl)
Methoxy-substituted phenyl group (3-chloro-4-methoxy-phenyl)

Potential Applications

Pharmaceutical research
Drug development

Structural Features

These features may make it suitable for binding to specific biological targets.

Research Need

Further research is required to fully understand its potential uses and effects in pharmaceutical applications.

Upstream product

• 118-48-9 isatoic anhydride 
• 5345-54-0 3-chloro-4-methoxyaniline 
• 610-14-0 2-nitrobenzyl chloride 

Relevant articles and documents

Identification of potent orally active factor Xa inhibitors based on conjugation strategy and application of predictable fragment recommender system

Anticoagulant agents have emerged as a promising class of therapeutic drugs for the treatment and prevention of arterial and venous thrombosis. We investigated a series of novel orally active factor Xa inhibitors designed using our previously reported conjugation strategy to boost oral anticoagulant effect. Structural optimization of anthranilamide derivative 3 as a lead compound with installation of phenolic hydroxyl group and extensive exploration of the P1 binding element led to the identification of 5-chloro-N-(5-chloro-2-pyridyl)-3-hydroxy-2-{[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}benzamide (33, AS1468240) as a potent factor Xa inhibitor with significant oral anticoagulant activity. We also reported a newly developed Free-Wilson-like fragment recommender system based on the integration of R-group decomposition with collaborative filtering for the structural optimization process.

Development of 2-thioxoquinazoline-4-one derivatives as dual and selective inhibitors of dynamin-related protein 1 (Drp1) and puromycin-sensitive aminopeptidase (PSA)

An established inhibitor ot dynamin-related protein 1 (Drp1), 3-(2,4-dichloro-5-methoxyphenyl)- 2- thioxoquinazoline-4-one (mdivi-1), was recently reported also to show potent puromycin-sensitive aminopeptidase (PSA)-inhibitory activity. Herein, we report structural development of mdivi-1 derivatives and structure-activity relationship (SAR) analysis of the synthesized compounds, as well as the structurally related PSA-specific inhibitor 3-(2,6-diethylphenyl)quinazoline-2,4-dione (PAQ-22), with the aim of identifying key structural features for inhibitory activity in order to develop selective inhibitors of Drpl, which is a potential target for treatment of Huntington's disease. Among the synthesized compounds, 3-(4-chloro3methoxyphenyl)-2-thioxoquinazoline-4-one 10g) exhibited more potent Drpl-inhibitory activity than mdivi-1 with high selectivity for Drpl over PSA.